Oncotarget: Championing for Impact of Oncology Research

One of the toughest challenges facing the fight against many diseases including cancer is availability and accessibility of information. Cancer research aimed at establishing research-based diagnostic, treatment and management procedures has spiked over the years due to the increased number of cancer-related deaths globally. Availing this information to the scientific communities and the rest of the population is an important step towards eliminating the scourge. One organization that is actively participating in the active generation and dispensation of research-based cancer related information is Oncotarget; a medical journal published weekly.

Rising Popularity Within Scientific Cycles

Established in 2010, Oncotarget’s popularity within the scientific cycles has soared over the years. Published weekly by Impact Journals under the sponsorship of Gordon Research Conference, the journal carries insightful researched articles authored by several researchers and scientists who are committed to advancing knowledge on cancer. The articles are very constructive and have contributed immensely towards advancing understanding of various aspects of cancer. As an open source weekly journal, the journal facilitates punctual access to information by removing the financial barrier that has the potential of curtailing cancer research and information dispensation. Additionally, multiple peer reviews ensure that the information presented for consumption is thoroughly vetted by qualified professionals. This has enabled the journal gain a respectable 5.008 when its impact factor is measured. The journal’s artciles have been cited over ten thousand times. Scopus/SJR currently ranks the journal as Q1, the highest distinction in ranking journals. Check the journal at SCImago Journal & Country Rank.

Another success factor is its online publication, which allows for ease of access for many research consumers globally. This is complimented by a special printed issue. Moreover, the journal uses a multidisciplinary approach as it publishes researches touching on various fields beyond cancer. Read more about Oncotarget at Bioxbio.

Editor-in-Chief: Mikhail Blagosklonny

Oncotarget’s popularity has also been drive by the highly qualified professionals who serve on its editorial board. Editorial board is comprised of individuals with a strong background in biology, medicine, cell and molecular biology, oncology and scientific research. They also have years of experience in their various fields. The journal’s current editor-in-chief,Mikhail Blagosklonny, is a professor of oncology and research scientist who specializes in cancer treatment and therapies including anti-aging therapies.

Learn more: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget

Inside Mikhail Blagosklonny’s Cancer And Anti-Aging Research

Dr. Mikhail Blagokslonny is a professor and researcher at the Roswell Park Cancer Institute in New York. As a Professor he teaches students about the field of Oncology in the Department of Cell Stress Biology. His research is primarily focused on discovering effective cancer treatments as well as research into anti-aging therapies. He earned both his PhD and M.D. at the First Pavlov State Medical University of St. Peterburg where he graduated with degrees in cardiology and experimental medicine. His specialties as a scientist are in Oncology, Hematology, and performing clinical trials. Follow Mikhail on Google Scholar

Dr. Blagosklonny has heavily researched the cancer drug rapamycin and how it could be a key to anti-aging. He has tested his hypothesis about how rapamycin extends life as it inhibits TOR signaling which regulates cell growth and metabolism. He is known in the field of medicine as one of the strongest advocates of using rapamycin in longevity research. Among his many research papers he has also created the hyper-function theory of aging in which he hypothesizes that aging is the result of an accumulation of molecular damage.

There are a number of peer-reviewed journals that Dr. Mikhail Blagosklonny is the editor-in-chief of. These journals include Oncotarget, Cell Cycle, and Aging. He is also the editor of Cell Death & Differentiation and the associate editor of Cancer Biology & Therapy, Cancer Biology & Therapy, Autophagy, International Journal of Cancer, and other medical journals. Mikhail Blagosklonny has also written over 300 research papers, book chapters, and reviews himself. His research has generated over 25,000 citations in other research papers.

Check Mikhail’s profile in LinkedIn